Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388089 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00388089 is a Phase 1 study that has completed, run by University of California, Davis. The registered enrollment target is 24 participants.
The verdict
NCT00388089, a Phase 1 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with topotecan may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and topotecan in treating patients with advanced solid tumors.
Interventions
- OTHER immunohistochemistry staining method
- OTHER flow cytometry
- DRUG bortezomib
- DRUG topotecan hydrochloride
- OTHER immunoenzyme technique
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388089
The ClinicalTrials.gov registry entry for NCT00388089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which immunohistochemistry staining method is the first listed.
NCT00388089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388089 about?
NCT00388089 is a clinical study titled "Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib t...
What is the current status of trial NCT00388089?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2004-12. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00388089?
The interventions under investigation include: immunohistochemistry staining method (OTHER), flow cytometry (OTHER), bortezomib (DRUG), topotecan hydrochloride (DRUG), immunoenzyme technique (OTHER).
Who is sponsoring clinical trial NCT00388089?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.